At a glance

What it is

Two very different ways to take one drug

Minoxidil was first made as a blood pressure drug. Patients on the tablets grew extra hair, which led to the scalp products. It widens blood vessels. Unlike finasteride, it does not block DHT, so it works through a different route. Many men use finasteride and minoxidil together for that reason.

The scalp foam or solution is FDA-approved for hair loss. The tablet is FDA-approved only for hypertension that is severe and not controlled by other medicines. Its label opens with a boxed warning that it can cause pericardial effusion, fluid around the heart, occasionally progressing to tamponade, and can worsen angina. The label also states that use of minoxidil tablets to promote hair growth is not an approved indication.

Low-dose oral minoxidil for hair is therefore off-label. The doses used for hair are a small fraction of the blood pressure doses, but that does not make the drug harmless, and the physician decides if it fits you.

Topical

Topical minoxidil: what the trial showed

In a 48-week trial, 393 men aged 18 to 49 used 5% minoxidil (157 men), 2% minoxidil (158) or placebo (78) twice daily. At 48 weeks the 5% solution was superior to 2% and placebo for change in hair count, for patient ratings and for investigator ratings of scalp coverage. Itching and local irritation were more common with 5% (Olsen 2002).

The over-the-counter label for men says results may begin at 2 months, that some men need at least 4 months, that it will not work for all men, and that continued use is needed or hair loss will begin again. It also says to ask a doctor first if you have heart disease, and to stop and ask a doctor if you get chest pain, rapid heartbeat, faintness, dizziness, sudden weight gain, or swelling of the hands or feet.

Low-dose oral

Low-dose oral minoxidil: what the evidence shows

The oral evidence is newer and smaller. In a double-blind trial in Brazil, 90 men with pattern loss were randomized to 5 mg of oral minoxidil daily or 5% topical twice daily for 24 weeks, and 68 finished. Terminal hair density did not differ significantly between the groups in the front or the crown. Photographs favored oral at the crown, not the front (Penha 2024). Hypertrichosis affected 22 of 45 men on the pill (49%), and headache 6 of 45 (14%).

A smaller trial of 65 people compared 1 mg oral with 5% topical for six months. Both improved hair diameter, and the difference between them was not significant (Asilian 2024). A network meta-analysis of 23 male studies found oral 5 mg grew more terminal hair at 24 weeks than topical 2% or 5%, and more than finasteride 1 mg. Those are indirect comparisons across trials with different designs, so read them as a rough guide only.

Dosing

How the dosing differs

• Topical. The men’s foam label directs half a capful applied to the scalp twice daily. More does not give a better result.
• Low-dose oral. Studies used doses from 0.25 mg to 5 mg a day. Tablets come in larger strengths made for blood pressure, so low doses are made by splitting tablets or by compounding. Compounded medications are not FDA-approved, and not evaluated for safety, effectiveness or quality.
• Titration. A physician starts low and raises the dose only if blood pressure, pulse and swelling stay stable.

A review of oral minoxidil adverse events noted that serious reactions such as pericardial effusion were extremely rare and often linked to compounding errors that produced an excessive dose. Dose accuracy matters.

Side effects

Side effects and warnings

A retrospective study of 1,404 people on low-dose oral minoxidil for at least three months (943 women, 461 men, mean age 43) reported the following. Hypertrichosis, extra hair growth on the face or body, was the most frequent at 15.1%, and 14 people stopped for that reason. Systemic effects were less common: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital edema 0.3% and insomnia 0.2%. 1.2% stopped for systemic effects. No life-threatening events were seen. The study had no control group (Vano-Galvan 2021).

Pericardial effusion needs its own paragraph. An analysis of 2,747 oral minoxidil reports in the FDA adverse event database found that pericardial effusion was more likely than other events to resolve after the drug was stopped. Spontaneous reports cannot prove cause, and the number of people taking the drug is unknown. The same analysis noted a handful of reports with topical minoxidil. Call your physician for chest pain, shortness of breath, a fast heartbeat, fainting, or rapid weight gain.

Who should not take it

Who should avoid minoxidil, or use extra caution

• Pheochromocytoma and known allergy to minoxidil: the tablet label lists these as contraindications.
• Heart failure, coronary disease, a prior pericardial effusion, a significant rhythm problem, or a history of fluid retention: oral use is usually not appropriate.
• Low blood pressure, or high blood pressure treated with several medicines.
• Pregnancy and breastfeeding: the over-the-counter label warns it may be harmful. Do not use it without your physician.
• Anyone who cannot be reached for monitoring in the first months.

Oral minoxidil lowers blood pressure, and so does tadalafil. If you take both, tell your physician so the combination is watched. See our tadalafil page.

Monitoring

Monitoring and stopping

For the oral form, I want blood pressure, pulse, weight and any swelling recorded before you start and checked after each dose change. You should know the stop list from the label: chest pain, rapid heartbeat, faintness or dizziness, sudden weight gain, swollen hands or feet. The over-the-counter label gives the same stop list for the scalp product.

Hair loss will begin again if you stop, as the topical label says. Gains from the oral form are expected to depend on continued use too. If shedding or thinning continues after about six months of steady use, tell your physician.

Women

A brief note on women

Topical minoxidil also has FDA-approved products for women. Low-dose oral minoxidil for women is off-label, and the same cautions apply. Finasteride is not for women who are or may become pregnant. Hair thinning in women has many causes, such as thyroid, iron and hormone changes, and needs an evaluation first.

Summit’s role

What Summit does with minoxidil

Summit Men includes oral finasteride or minoxidil, with labs. Dr. Miranda decides whether minoxidil fits you after your history and labs, including blood pressure, heart history and your other medicines, and which form, topical or low-dose oral, is appropriate. Summit is telehealth only.

• Low-dose oral minoxidil for hair loss is off-label, and the physician decides.
• Compounded low-dose preparations are not FDA-approved or evaluated for safety, effectiveness or quality.
• Cost is on our pricing page. See also our testosterone page, since testosterone can speed thinning in men prone to it.

Keep reading

Related medications

Sources

Where this comes from

All retrieved November 10, 2026.

1. Kenvue. Men’s Rogaine (minoxidil) foam, over-the-counter drug facts. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b5e2860-6855-4a65-8bbc-e064172a1adf
2. Minoxidil tablets, prescribing information (boxed warning, indication, unapproved use). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc9f21d-c959-89ee-e063-6294a90a0a62
3. Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002. https://pubmed.ncbi.nlm.nih.gov/12196747/
4. Penha MA, et al. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol 2024. https://pubmed.ncbi.nlm.nih.gov/38598226/
5. Asilian A, et al. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. J Cosmet Dermatol 2024. https://pubmed.ncbi.nlm.nih.gov/38031516/
6. Gupta AK, et al. Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol 2022. https://pubmed.ncbi.nlm.nih.gov/35107565/
7. Vano-Galvan S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol 2021. https://pubmed.ncbi.nlm.nih.gov/33639244/
8. Jimenez-Cauhe J, et al. Characterization and management of adverse events of low-dose oral minoxidil treatment for alopecia: a narrative review. J Clin Med 2025. https://pubmed.ncbi.nlm.nih.gov/40142611/
9. Gupta AK, et al. The role of patient- and drug-related factors in oral minoxidil and pericardial effusion: analyses of data from the FDA Adverse Event Reporting System. J Cosmet Dermatol 2025. https://pubmed.ncbi.nlm.nih.gov/39686699/